12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Denosumab regulatory update

Amgen said FDA accepted for review an sBLA for Prolia to increase bone mass in men with osteoporosis at high risk for fracture. The PDUFA date is Sept. 20. Denosumab is approved as Prolia in the U.S. and...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >